Stock On Watch: Lion Biotechnologies Inc (NASDAQ:LBIO) Institutional Investors Quarterly Sentiment

November 23, 2016 - By Winifred Garcia   ·   0 Comments

Stock On Watch: Lion Biotechnologies Inc (NASDAQ:LBIO) Institutional Investors Quarterly Sentiment

Sentiment for Lion Biotechnologies Inc (NASDAQ:LBIO)

Lion Biotechnologies Inc (NASDAQ:LBIO) institutional sentiment increased to 1.74 in Q2 2016. Its up 0.07, from 1.67 in 2016Q1. The ratio improved, as 45 investment managers started new or increased holdings, while 27 decreased and sold stock positions in Lion Biotechnologies Inc. The investment managers in our partner’s database now possess: 42.74 million shares, up from 36.71 million shares in 2016Q1. Also, the number of investment managers holding Lion Biotechnologies Inc in their top 10 holdings increased from 2 to 4 for an increase of 2. Sold All: 9 Reduced: 18 Increased: 36 New Position: 9.

Lion Biotechnologies, Inc. is a clinical-stage biotechnology company. The company has a market cap of $448.59 million. The Firm is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. It currently has negative earnings. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma.

About 8,859 shares traded hands. Lion Biotechnologies Inc (NASDAQ:LBIO) has risen 20.83% since April 21, 2016 and is uptrending. It has outperformed by 15.50% the S&P500.

According to Zacks Investment Research, “Lion Biotechnologies, Inc. is developing autologous cell therapies for the treatment of cancer. The Company’s lead product candidate, C?ntego(TM), is an autologous cell therapy indicated for the treatment of metastatic melanoma. Lion Biotechnologies, Inc., formerly known as Genesis Biopharma, Inc., is based in Woodland Hills, California.”

Acuta Capital Partners Llc holds 12.58% of its portfolio in Lion Biotechnologies Inc for 3.23 million shares. Venbio Select Advisor Llc owns 4.34 million shares or 7.81% of their US portfolio. Moreover, Broadfin Capital Llc has 2.5% invested in the company for 3.17 million shares. The New York-based Perceptive Advisors Llc has invested 2.03% in the stock. Ghost Tree Capital Llc, a New York-based fund reported 700,000 shares.#img1#

Insider Transactions: Since January 1, 0001, the stock had 0 buys, and 1 sale for $491,740 net activity.

LBIO Company Profile

Lion Biotechnologies, Inc., incorporated on September 17, 2007, is a clinical-stage biotechnology company. The Firm is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

More notable recent Lion Biotechnologies Inc (NASDAQ:LBIO) news were published by: Fool.com which released: “Why Lion Biotechnologies Inc. Stock Is Roaring Higher Today” on June 03, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on November 20, 2013, Marketwired.com published: “Lion Biotechnologies to Present at the 28th Annual Piper Jaffray Healthcare …” on November 23, 2016. More interesting news about Lion Biotechnologies Inc (NASDAQ:LBIO) were released by: Thestreet.com and their article: “Lion Biotechnologies: Is This Tiny Biotech Company Ready to Roar?” published on June 06, 2016 as well as Quotes.Wsj.com‘s news article titled: “News Lion Biotechnologies Inc.LBIO” with publication date: August 14, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Winifred Garcia


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>